Serial No.:

To Be Assigned

Case No.:

T1618P

Page

3

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-11 without prejudice and insert therefore new Claims 12-33. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-11 (canceled)

12. (new) A method for treating age-related cognitive decline or mild cognitive impairment in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of the compound of formula I:

or a pharmaceutically acceptable salt thereof.

- 13. (new) The method of Claim 12 wherein the patient is a person aged 55 or over.
- 14. (new) The method of Claim 1'3 wherein the patient is a person aged 60 or over.
- 15. (new) The method of Claim 14 wherein the patient is a person aged 65 or over.

Serial No.:

Case No.:

To Be Assigned T1618P

Page

4

16. (new) The method of Claim 12 wherein the patient possesses one or more risk factors for developing Alzheimer's disease selected from: a family history of Alzheimer's disease; a genetic predisposition to Alzheimer's disease; elevated serum cholesterol; adult-onset diabetes mellitus; raised cerebro-spinal fluid levels of total tau; raised cerebro-spinal fluid levels of phospho-tau; and lowered cerebro-spinal fluid levels of $A\beta42$.

- 17. (new) The method of Claim 12 wherein the patient suffers from mild cognitive impairment.
- 18. (new) The method of Claim 12 wherein the patient suffers from age-related cognitive decline.
- 19. (new) The method of Claim 12 wherein the treatment of age-related cognitive decline or mild cognitive impairment in a human patient comprises preventing, retarding or arresting the accumulation of insoluble $A\beta$ in the brain of the patient suffering from age-related cognitive decline or mild cognitive impairment.
- 20. (new) A method for preventing or delaying the onset of Alzheimer's disease in a human patient suffering from age-related cognitive decline or mild cognitive impairment comprising administering to the patient a therapeutically effective amount of the compound of formula I:

or a pharmaceutically acceptable salt thereof.

Serial No.:

To Be Assigned

Case No.:

T1618P

5

Page

21. (new) The method of Claim 20 wherein the patient is a person aged 55 or over.

- 22. (new) The method of Claim 21 wherein the patient is a person aged 60 or over.
- 23. (new) The method of Claim 22 wherein the patient is a person aged 65 or over.
- 24. (new) The method of Claim 20 wherein the patient additionally possesses one or more risk factors for developing Alzheimer's disease selected from: a family history of Alzheimer's disease; a genetic predisposition to Alzheimer's disease; elevated serum cholesterol; adult-onset diabetes mellitus; raised cerebro-spinal fluid levels of total tau; raised cerebro-spinal fluid levels of phospho-tau; and lowered cerebro-spinal fluid levels of $A\beta42$.
- 25. (new) The method of Claim 20 wherein the patient suffers from mild cognitive impairment.
- 26. (new) The method of Claim 20 wherein the patient suffers from age-related cognitive decline.
- 27. (new) A method for preventing or delaying the onset of dementia associated with Alzheimer's disease in a patient suffering from age-related cognitive decline or mild cognitive impairment comprising administering to the patient a therapeutically effective amount of the compound of formula I:

Serial No.: To Be Assigned

Case No.: T1618P

Page 6

or a pharmaceutically acceptable salt thereof.

- 28. (new) The method of Claim 27 wherein the patient is a person aged 55 or over.
- 29. (new) The method of Claim 28 wherein the patient is a person aged 60 or over.
- 30. (new) The method of Claim 29 wherein the patient is a person aged 65 or over.
- 31. (new) The method of Claim 27 wherein the patient additionally possesses one or more risk factors for developing Alzheimer's disease selected from: a family history of Alzheimer's disease; a genetic predisposition to Alzheimer's disease; elevated serum cholesterol; adult-onset diabetes mellitus; raised cerebro-spinal fluid levels of total tau; raised cerebro-spinal fluid levels of phospho-tau; and lowered cerebro-spinal fluid levels of $A\beta42$.
- 32. (new) The method of Claim 27 wherein the patient suffers from mild cognitive impairment.
- 33. (new) The method of Claim 27 wherein the patient suffers from age-related cognitive decline.